12885_2020_7732_MOESM2_ESM.zip (43.68 kB)
Additional file 2 of Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
dataset
posted on 2021-01-16, 04:30 authored by Jiri Minarik, Tomas Pika, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Ludek Pour, Petr Pavlicek, Martin Mistrik, Lucie Brozova, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Jaroslav Bacovsky, Lenka Capkova, Michal Sykora, Petr Kessler, Lukas Stejskal, Adriana Heindorfer, Jana Ullrychova, Tomas Skacel, Vladimir Maisnar, Roman HajekAdditional file 2: Supplementary Table 2a. Association of OS with selected variables. Supplementary Table 2b Association of OS with selected variables in multivariable analysis – Paired analysis.
